Lorlatinib Induced Non-cardiogenic Pulmonary Edema. [PDF]
Matsuoka S +8 more
europepmc +1 more source
Antibiotic Mechanisms and Resistance: Molecular Insights and Therapeutic Strategies. [PDF]
Ma H +7 more
europepmc +1 more source
Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance. [PDF]
Wilson D +6 more
europepmc +1 more source
Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report. [PDF]
Wu JL, Iams WT.
europepmc +1 more source
Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China. [PDF]
Chen Z, Tang C, Ma X, Tian P, Gong L.
europepmc +1 more source
Cabozantinib overcomes ROS1 L2086F NSCLC resistance to lorlatinib: A case report. [PDF]
Liu X, Chen Q, Shao L, Luo P, An JH.
europepmc +1 more source
Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell lung cancer patient with severe tumor-associated liver failure: A case report. [PDF]
Kunimasa K +11 more
europepmc +1 more source
Novel macrocyclic peptidomimetics targeting the insulin-regulated aminopeptidase (IRAP): design, synthesis and evaluation. [PDF]
Olaniran Håkansson E +9 more
europepmc +1 more source
Empowering molecular complexity <i>via</i> biocatalysis: emerging blueprints in the total synthesis of medicinally relevant natural products. [PDF]
Yadav RN +6 more
europepmc +1 more source

